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Abstract: 
Background 
The complexity and cost of treating cancer patients is escalating rapidly and increasingly difficult 
decisions are being made regarding which interventions provide value for money. BioGrid 
Australia supports collection and analysis of comprehensive treatment and outcome data across 
multiple sites. Here we use preliminary data regarding the National Bowel Cancer Screening 
Program (NBCSP) and stage-specific treatment costs for colorectal cancer (CRC) to 
demonstrate the potential value of real world data for cost-effectiveness analyses (CEA).  
Methods 
Data regarding the impact of NBCSP on stage at diagnosis was combined with stage-specific 
CRC treatment costs and existing literature.  An incremental CEA was undertaken from a 
government healthcare perspective, comparing NBCSP to no-screening. The 2008 invited 
population (n=681,915) was modelled in both scenarios.  Effectiveness was expressed as CRC-
related life years saved (LYS).  Costs and benefits were discounted at 3% per annum.   
Results 
Over the lifetime and relative to no-screening, NBCSP was predicted to save 1,265 life-years, 
prevent 225 CRC cases and cost an additional $48.3 million, equivalent to a cost-effectiveness 
ratio of $38,217 per LYS.  A scenario analysis assuming full participation improved this to 
$23,395.   
Conclusions 
This preliminary CEA based largely on contemporary real world data suggests population-based 
FOBT screening for CRC is attractive. Planned ongoing data collection will enable repeated 
analyses over time, using the same methodology in the same patient populations, permitting an 
accurate analysis of the impact of new therapies and changing practice. Similar CEA using real 
world data related to other disease types and interventions appears desirable.  
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Introduction 
In Australia, colorectal cancer (CRC) is the second most common cancer and second most 
common cause of cancer-related mortality1.  Three large randomised studies have 
demonstrated that biennial faecal occult blood test (FOBT) screening significantly reduces CRC 
mortality, largely due to diagnosis of CRC at earlier curable stages2-4.  In Australia, biennial 
FOBT screening was deemed feasible, acceptable and cost-effective in a pilot study5, leading to 
implementation of the National Bowel Cancer Screening Program (NBCSP) in 2006. The 
NBCSP was most recently inviting Australians aged 50, 55 and 65 years to undergo a FOBT6.  
Future expansion of the eligible population is being considered.   The NBCSP recommends 
symptomatic persons and those with a family history seek medical advice rather than participate 
in screening5. 
 
Previous cost-effectiveness analyses (CEA) have concluded that population FOBT screening is 
cost-effective5,7-8.  However, these had consistent and specific limitations, including an exclusive 
reliance on clinical trial data to determine the impact of FOBT testing in the general population. 
This is particularly relevant given the repeated demonstrations of wide variations when 
comparing outcomes achieved in fit and motivated patients within carefully conducted and 
monitored clinical trials, to the outcomes observed in real world patient populations9.   Further 
limitations of these CEA include the absence of comprehensive hospital and community based 
costing data and patient survival; one study substituted Australian survival data with more 
modern survival data from the USA in a sensitivity analysis which moved the result to well 
above the acceptable cost-effectiveness threshold8.  Finally, as practice evolves year by year, 
any analyses relying on published data to determine treatment costs10 and survival rates11 
which are inevitably outdated by time of publication, becomes increasingly less relevant to 
current practice.   
 
Using BioGrid data we have previously reported on the impact of the NBCSP on colorectal 
cancer stage at diagnosis12, demonstrating within the community setting, that FOBT screening 
led to an increased number of early stage cancers and a marked fall in late stage cancers, 
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when compared to patients presenting with symptomatic disease.  In a separate analysis of 
comprehensive treatment and outcome data from 4 Melbourne hospitals, we showed that the 
cost of treating CRC was rapidly escalating; the cost of treating CRC in Australia is likely to be 
around $1,210 Million in 2011 (2008 prices) 13, approximately four times the equivalent cost 
reported for 2001 14.   
 
Here we seek to demonstrate that comprehensive real world treatment data, where 
standardised data collection, and data collation and analysis is supported by BioGrid Australia 
(www.biogrid.org.au), can be used to reflect both the real impact of FOBT screening in the 
general population and the true stage specific cost of treating colorectal cancer. Another 
potential advantage, along with using real world data, is that analyses are as current as 
possible, and could be repeated and updated on a regular basis rather than being applied as a 
stand alone CEA.  
 
 
Method 
Research Design 
An incremental cost-effectiveness analysis was undertaken from a government healthcare 
perspective.  Net costs and effectiveness of the NBCSP were compared to a no-screening 
scenario.   Costs analysed are associated with invitation and screening, diagnosis, adenoma 
surveillance and CRC treatment.   Effectiveness results are expressed as life years saved from 
the NBSCP.  The year 2008 was nominated as the reference year due to availability of detailed 
program data.  Costs and benefits were discounted at 3% per annum.   
 
Eligible Population  
The population invited to participate in the NBCSP in 2008 included 681,915 Australians aged 
50, 55 and 6510.  This population was modelled in both scenarios.   
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Modelling 
A decision analytic model (Figure-1) was developed to estimate lifetime costs and benefits 
associated with the NBCSP. The eligible population enters the model and screening and 
diagnostic pathways were estimated based on participation rates, diagnostic results and the 
incidence of adenomas and CRC. Seven health states are assigned to the eligible population 
(clear, low and high risk adenomas and CRC Stage 1 through 4). For those diagnosed with 
adenomas, surveillance colonoscopy costs were applied to all cases and treatment cost savings 
and life years saved due to CRC prevented were applied to a proportion of cases. Treatment 
costs and life years lost were applied to persons diagnosed with CRC based upon stage of 
disease. NBCSP invitees who do not participate in the recommended healthcare pathways were 
assumed to incur costs up to the point of drop-out and to have the same outcomes as the no-
screening scenario.  
 
The no-screening scenario assumed no FOBT screening and adopted incidence rates for 
adenoma and CRC from no-screening reference populations. Many variables are provided for 
“screened” and “unscreened” persons. People in the NBCSP scenario who chose not to 
participate are assigned the same values as the no-screening scenario.  
 
Screening participation rates, outcomes and costs  
Screening costs relate to FOBT invitation and screening.  Costs include program administration, 
FOBT kits, pathology testing, telephone helplines and a National CRC register. The Australian 
Government allocated $87.4 million over 3 years for the NBCSP’s second phase6. An estimate 
of $30.8 million for the program in 2008 is adopted within our analysis. For the NBCSP 
scenario, age-specific rates of FOBT screening participation and positive FOBT results were 
sourced from the NBCSP Monitoring Report6 (Figure-1).  For the no-screening comparator, we 
assumed no opportunistic FOBT screening and therefore no-screening costs.   
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Diagnostic participation rates and costs  
For screened persons, diagnostic costs were applied to individuals with positive FOBT results 
and include general practitioner (GP) consultation and colonoscopy costs. Rates of GP 
consultation and colonoscopy reported by the NBCSP Monitoring Report are presumed to be 
gross underestimations due to low rates of clinician feedback6. However, the report describes 
that 91.7% of those recorded as consulting their GP proceeded to have a colonoscopy. Our 
model assumes 90% of persons with positive FOBT consult their GP and 91.7% of those 
consulting a GP will complete a colonoscopy.  For unscreened patients, diagnostic costs were 
applied to all persons diagnosed with adenoma or CRC.  GP costs were sourced from the 
Medicare Benefits Schedule November 2008 (item 23) and colonoscopy costs (accounting for 
complication rates15) from the Victorian Public Hospital’s casemix funding model.  We assumed 
all diagnostic costs occurred in the year of screening. 
 
Adenoma incidence and surveillance costs 
For screened persons, low/high risk adenoma incidence rates were sourced from the NBCSP 
Monitoring Report6.  For unscreened patients, incidence rates for “diagnosed” low/high risk 
adenoma were adopted from the control group of a pivotal FOBT screening study2 (Table-1). 
Most adenomas in unscreened populations are undetected. Both references defined high-risk 
adenomas as greater than 10mm.  Following identification and resection of adenoma(s), 
patients undergo lifetime surveillance through regular colonoscopies.  The NHMRC 
recommends 5 and 3 yearly surveillance colonoscopies for completely resected low and high 
risk adenomas respectively16.  Consultation with experts have led us to assume that on 
average, surveillance colonoscopies are performed at half this frequency (10 and 6 yearly) due 
to poor patient/clinician compliance and many older patients being unfit for colonoscopy. 
Surveillance intervals, colonoscopy costs and life expectancy were combined to calculate age-
specific, lifetime adenoma surveillance costs.  
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CRC incidence, stage at diagnosis and treatment costs 
Our analysis assumes an equal incidence of CRC in both the NBCSP and no-screening 
scenarios. Recently published age-specific CRC incidence rates were adopted1.  In the context 
of biennial screening, our model assumes the expected number of CRC cases is the sum of 
incidence over two consecutive years.   
  
The stage distribution of CRC at diagnosis for both screened and unscreened patients was 
sourced from an analysis of the impact of the Australian NBCSP12 (Table-2).  Screen-detected 
CRC stage distribution was only applied to patients completing the recommended healthcare 
pathway. The sensitivity of immunochemical FOBT and colonoscopy were also accounted for at 
66%17 and 95%16 respectively. For screened patients with undetected CRC, the stage 
distribution of unscreened patients was applied. 
 
Ananda et al. developed a model which calculated CRC treatment costs for stage 1 CRC, stage 
2 colon cancer, stage 3 colon cancer, stage 2/3 rectal cancer and stage 4 CRC 13.  This model 
used data from 3,012 patients with CRC diagnosed between January 2003 and December 
2008.  For our study, this model was adjusted to determine treatment costs for stage 1 through 
4 CRC.  These stage specific treatment costs are listed in Table-2.  Based on clinical 
experience, we assumed half the treatment costs fell in the screening year and the remainder in 
the following year. 
 
Years of life lost (YLL) averted (earlier stage diagnosis) 
YLL due to CRC were applied to participants diagnosed with CRC in 2008 based on stage of 
diagnosis in both scenarios. Stage-specific five-year survival rates (5YS) and median survival 
for non-survivors were sourced from the BioGrid Australia dataset used in the treatment cost 
model (Table-2).   The 5YS analysis was based upon patients in this cohort with available 
survival data (n=2,818), from which the median follow up was 6.9 years.  YLL for non-survivors 
were calculated as the difference between median survival and age-specific life expectancy18.  
Analyses assumed that patients surviving beyond 5 years revert to normal life expectancy. 
 
 
 8
Survival benefits gained as a consequence of lead-time bias were accounted for using stage-
specific sojourn times19.  
 
YLL averted (CRC prevention)  
High-risk adenomas have the potential to progress to CRC. A study of the natural history of 
CRC describes 8% of high risk adenomas transforming to CRC at 10 years (increasing to 24% 
at 20 years)20, whilst a review confirmed that resection and subsequent surveillance of high-risk 
adenomas can reduce colorectal cancer incidence by 76-90%21. Our analysis conservatively 
assumes that without intervention, 8% of high-risk adenomas diagnosed during the screening 
year (2008) would transition to CRC at 10 years and that 75% of these cases are prevented due 
to their resection/surveillance.  We assumed that CRC cases prevented had the same stage 
distribution as unscreened patients.  Treatment cost offsets and life years saved are captured 
for each CRC case prevented. 
 
Scenario Analyses 
We extrapolated costs and benefits to the future eligible NBCSP population to simulate the 
impact of introducing older age groups where different participation and incidence rates are 
observed1,6.  The population was sourced from the Australian Bureau of Statistics22. Data for 50, 
55 and 65 year olds was applied to age groups 50-54, 55-59 and 65-69, and a “line of best fit” 
was utilised to estimate the same data for 60-64 and 70-74 age groups. The NBCSP budget 
(screening costs) was increased proportionally with the number of persons screened. Other cost 
assumptions were the same as the primary model.  Additional scenario analyses include 
increasing FOBT participation rates (25% increase, 50% increase and 100% participation), 
adopting alternative UK 5YS rates based on a larger patient cohort, but not age-specific to the 
target population23, adopting NHMRC guidelines for adenoma surveillance frequencies, 
increasing the proportion of CRC prevented by adenoma resection/surveillance to the maximum 
rate (90%) observed in previous clinical trials, and adjusting the discount rate to 0%.  We also 
simulated the impact of re-inviting 390,000 people who received defective FOBT kits, as 
reported by the Department of Health and Aging.
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Results 
In 2008, 681,915 people were invited to participate in the NBCSP.  Modelling predicted that 
from this population, 1,664 CRC cases would be diagnosed in both scenarios, however, earlier 
stage diagnoses are seen in the NBCSP scenario. An additional 6,021 adenomas diagnosed in 
the NBCSP scenario was also projected. Relative to the no screening scenario, the lifetime 
benefits from screening included 1,265 life years saved (LYS) and 225 CRC cases prevented. 
The NBCSP scenario resulted in additional screening, diagnostic and surveillance costs, partly 
offset by savings in CRC treatment costs. The total additional cost for the NBCSP scenario was 
$48.3 million.  The resulting cost-effectiveness ratio is $38,216 per LYS (Table-3). 
 
All scenario analyses improved cost-effectiveness with three exceptions:  introducing the cost of 
re-invitations for faulty FOBT kits and the use of outdated stage specific costs led to a cost-
effectiveness ratio marginally below the acceptable range, whilst adopting NHMRC guidelines 
for adenoma surveillance resulted in a ratio slightly above the acceptable range (Table-4). The 
full participation and zero discounting scenarios had the greatest impact, each decreasing the 
cost-effectiveness ratio to below $25,000 per LYS. 
 
Discussion 
In Australia, an intervention is deemed sufficiently cost-effective for implementation if it costs 
less than $50,000 per LYS8.  Approved screening programs for breast and cervical cancer are 
well within this range8. Our study suggests that the NBCSP, as implemented in 2008, is cost-
effective at $38,216 per LYS.  
 
Our methods are notable for several reasons.  We adopted contemporary treatment costs 
derived from comprehensive treatment data across 4 hospitals that account for current 
treatment protocols.  Table-2 compares the costs adopted by our analysis to lower costs 
reported by O’Leary et al. that were adopted in previous cost effectiveness analyses10. Survival 
data is also current and representative of the Australian population. Calculated benefits from the 
NBCSP were based upon an up to date analysis of the impact of the Australian NBCSP on 
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stage at CRC diagnosis.  Finally, we utilised observed NBCSP screening costs, rates of 
participation and positive FOBT6.   
 
Previous cost effectiveness analyses of the NBCSP followed cohorts through regular screening 
from invitation until death8.  Our model is similar to that used by Stone et al (2000), where costs 
and benefits resulting from one representative year of the NBCSP are analysed7.  The strengths 
of the annual model are that observed rather than modelled data is utilised and methods are 
often more transparent.  However, factors related to repeat screening, such as the observation 
that repeated screening improves participation2 could not be captured.  Our model is 
conservative with regards to other timing related effects. We have excluded the anticipated 
higher number of CRC cases diagnosed early in a screening program. We have also assumed 
2008 was the first year of screening and therefore cases of CRC prevented are well into the 
future and heavily discounted, whilst most costs are undiscounted.  The large impact of 
discounting is illuminated by the 0% discount rate scenario analysis which almost halved the 
cost-effectiveness ratio. 
 
Diagnostic costs were $15.7 million higher in the screening scenario because colonoscopies are 
recommended for all persons with a positive FOBT. Approximately half the colonoscopies were 
estimated to reveal adenoma or CRC. Similarly, costs of lifetime adenoma surveillance were 
$14.7 million higher in the screening scenario due to the higher rate of adenoma detection.  
Consistent with expert advice, our study assumed less frequent adenoma surveillance than the 
NHMRC recommendations.  We believe our assumptions are an accurate reflection of actual 
practice, supported by previous cost effectiveness analyses7.  A scenario analysis adopting the 
NHMRC guidelines resulted in the NBCSP being marginally above the acceptable cost-
effectiveness threshold. However, our assumptions regarding CRC prevention due to adenoma 
resection/surveillance are very conservative which may counter any concerns regarding the 
frequency of colonoscopies adopted.  
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The 5YS adopted in this analysis, whilst calculated specifically for the Australian NBCSP target 
age group, is based upon a small number of patients.  We believe the rates capture advances in 
CRC treatment as demonstrated by survival improvements for Stage 3 and 4 when compared to 
McLeish et al data11 (Table-2). Our data shows superior survival compared to more modern UK 
rates23.  We believe this is due to our patient cohort being mostly treated in tertiary referral 
hospitals.   A scenario analysis using the poorer UK survival rates improved the NBCSP cost-
effectiveness because worse survival outcomes correlate to greater opportunities to save life 
years through screening (Table-4).   CRC survival is expected to improve further as survival 
benefits of recently funded treatments, such as bevacizumab and cetuximab, become evident.  
Therefore, we believe our superior survival rate assumptions are most appropriate. 
 
Screening interventions are dependent upon participation to realise health benefits.  The rates 
used in our study are observed data from the NBCSP in 2008 and are very poor, particularly for 
50 year olds (Figure-1).  Substantially higher participation rates for FOBT screening have been 
achieved in other countries2.  Results from our scenario analyses demonstrate that increased 
participation will lead to greater health benefits and cost-effectiveness. A movement from 
current to full participation will shift cost-effectiveness from $38,216 to $23,395 per life year 
saved. These results should be used as a further impetus to increase public education and 
awareness regarding both CRC and the NBCSP. 
 
In summary our preliminary data suggests the NBCSP is currently cost effective, however there 
are multiple limitations to our analyses and we would not suggest that this is definitive. The 
intent of this study however was to demonstrate that comprehensive real world data can be 
used to support cost effectiveness analyses based on contemporary data. Such analyses could 
be employed across many other scenarios where the cost-effectiveness of treatment is of 
particular interest. As the BioGrid data continues to be updated over time, repeated real time 
analyses would be possible, and would be of particular interest as new treatment options are 
introduced. Importantly, following the effort to perform the initial analyses, the same 
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methodology can be used in repeated interrogations of the data over time to produce valid 
comparisons with modest additional effort.  
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Tables 
Table 1 CRC and Adenoma incidence rates for 2008 
Age CRC  
Incidence rate 
(per 100,000 
person) 
Adenoma 
 Incidence rate in NBCSP 
(per 100,000 invitations 
using 2008 participation rates) 
Diagnosed Adenoma Incidence rate  
in unscreened population 
(per 100,000) 
Discounted Lifetime  
Cost of Adenoma 
surveillance 
(per adenoma) 
  Low Risk High Risk Low Risk High Risk Low Risk High Risk 
50-54 57.8 311 239 69 95 $2,268 $3,780 
55-59 94.7 313 544 29 40 $1,600 $3,200 
65-69 245.6 527 1144 58 81 $895 $2,686 
Source AIHW 20081 NBCSP Monitoring Report 2009 6 Kronborg et al. 2 Calculated 
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Table 2 CRC stage distribution, lifetime costs and survival data  
 
Impact of NBCSP on 
stage at diagnosis (17) 
(%) 
Cost  
(AUD$) 
5 Year Survival  
(%) 
Median Survival for non-
survivors 
(years) 
 
*Screening 
(n=40) 
*Unscreened 
(n=1588) 
*BioGrid 13 
(2011)* 
O’Leary 10 
(2004) 
*BioGrid 
(2003-2008) 
McLeish 11 
(1987) 
UK NCIN 23 
(1996-2002) 
*BioGrid 
(2003-2008) 
Stage 1 43% 17% $34,337 $17,148 84% 89% 93% 1.59 
Stage 2 27% 27% $53,487 $33,364 77% 79% 77% 2.12 
Stage 3 27% 28% $79,924 $25,771 64% 35% 48% 1.84 
Stage 4 3% 18% $71,156 $6,264 19% 1% 7% 0.94 
Notes: * adopted in primary cost-effectiveness analyses. Remaining data were utilised for scenario analysis or are included for comparison purposes. 
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Table 3 Cost-Effectiveness Analysis results for the NBCSP in 2008  
 NBCSP No-Screening Difference 
Costs (million)    
Screening Costs (including recruitment) 30.8 0.0 30.8 
Diagnostic Costs 19.9 4.2 15.7 
Adenoma Surveillance Costs  19.1 4.4 14.7 
CRC Treatment Costs (CRC patients)  97.0 99.8 -2.8 
CRC Treatment Cost Savings (CRC prevented) -12.7 -2.6 -10.1 
Total Costs 154.0 105.7 48.3 
Effectiveness    
Life years lived (CRC patients) 22,905 22,424 481 
Life years saved (CRC prevented)  784 0 784 
Total YLL averted 23,688 22,424 1,265 
Cost-Effectiveness    
Cost per life year gained 38,216   
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Table 4 Scenario analyses 
  NBCSP additional cost 
NBCSP 
additional LYS 
Cost per life year 
saved 
Primary analyses   48.3 1,265 $38,216 
Outdated costs Costs reported by O’Leary et al. 57.3 1,265 $45,341 
Expanded population Age 50-74 (n=5,317,282) 187.7 5,925 $31,686 
Participation 25% increase (mean 47%) 52.7 1,622 $32,501 
 50% increase (mean ~75%) 57.1 1,979 $28,849 
 Full participation (100%) 79.3 3,388 $23,395 
Survival UK NCIN 5 Year survival rates 48.3 1,607 $30,076 
Adenoma surveillance NHMRC guidelines for adenoma surveillance 65.6 1,265 $51,850 
Discounting No Discounting 51.4 2,171 $23,656 
CRC prevention 90% CRC prevented by adenoma resection 46.3 1,421 $32,572 
Faulty FOBT 390,000 Re-invitations 56.8 1,265 $44,897 
Note: all scenarios are univariate adjustments based on the primary analyses 
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Figures 
Figure 1 NBCSP Healthcare utilisation and outcomes pathway 
i Medical Benefits Schedule November 2008 
ii Weighted colonoscopy cost using complication rates from Vialla et al. 15  and costs from Victoria Public Hospitals (99.69% uncomplicated $1,162, 0.21% bleeding $7,070, 0.10% perforation 
$19,102) 
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Figures 
Figure 1 NBCSP Healthcare utilisation and outcomes pathway 
